RecruitingPhase 2

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

Egypt150 participantsStarted 2025-06-30

Plain-language summary

Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of controlled ovarian stimulation of gonadotrophin-Stimulated ovarian cycles. It is theorized to manifest systemically as a result of vasoactive mediators like vascular endothelium growth factor (VEGF) being released from hyperstimulated ovaries. As a result, capillary permeability is increased which causes the extravasation of fluid from the intravascular compartment into the third space. The haemoconcentration which ensues results in complications such as hypercoagulability and reduced end organ perfusion.

Who can participate

Age range20 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 18-38 years * Body mass index (calculated as weight in kilograms divided by the square of height in meters) \< 30 kg/m2. * A long luteal protocol is used for ovarian stimulation. * Day 2 FSH \<10 mIU/L and E2\< 50 pg/ml * High risk of OHSS, defined as having more than 20 follicles \>12 mm in diameter and/or E2 levels \> 3000 pg/ml when the size of the leading follicle is \> 15 mm Exclusion Criteria: The presence of chronic medical diseases, including liver cell failure, renal failure, uncontrolled hypertension, uncontrolled diabetes mellitus, or class 3 or 4 function heart disease in the New York heart association classification. Allergy to Cabergoline.

What they're measuring

Occurrence and severity of OHSS

Timeframe: 1 month

Trial details

NCT IDNCT07043322

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-20

View on ClinicalTrials.gov More Gynecologic Disease trials